Hepion Pharmaceuticals Inc., formerly ContraVir Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company. The Company is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. Its lead oral drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. CRV431 is also being developed for viral hepatitis-induced liver disease. CRV431 targets multiple biochemical pathways involved in the progression of liver disease.
http://contravir.com/© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd 由塞浦路斯证券交易委员会根据2015年9月25日发布的第281/15号许可证授权和监管。“Just2Trade”商标归LimeTrading（CY）有限公司所有。
注册号码: HE 341520
地址: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
免责声明：
本网站上的所有信息和材料未经许可不得使用。更多信息，请联系公司。
在金融市场上交易存在风险。投资产品可能会升值也可能会贬值，投资者可能会损失所有的本金。在涉及有杠杆的产品时，损失可能会大于初始本金。在金融市场上交易的风险信息可以在此查看 全面风险披露。
E-mail: 24_support@just2trade.online
